if you see the updated slide below, two points worth noting:
1) VP-002 is now PYC-001; which seems to indicate DR is now no longer a program/asset, and has been replaced with ADOA being the defined co-lead
2) 100% ownership for ADOA and all future Vision Pharma pipeline assets; may be a result of Lion Eye not taking up the last funding round?
For the pipeline CNS is still in the pipeline; but will likely remain undisclosed until IP is locked in
This aligns with Rohan’s presentation that 3 assets will be delivered this year, with a potential 4th as backup being worked up.
PYC, page-38
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.0¢ | $281.8K | 1.643M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 437743 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 133268 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |